Introduction
Anemia may contribute to adverse clinical outcomes in different populations, in particular in the elderly and in patients with chronic kidney disease (CKD) and/or chronic heart failure (CHF). [1] [2] [3] In the elderly, anemia is associated with higher mortality rates than in subjects with normal hemoglobin levels, 4, 5 and has a negative impact on the quality of life and physical functioning. 6, 7 In CKD, anemia is associated with abnormalities in left ventricular geometry, cardiovascular disease events and all-cause mortality. 8, 9 The prevalence of anemia has been studied in the setting of well-defined populations, such as CKD 10 or CHF patients 11 and cancer patients 12 , with extreme variation according to the study population and the criteria for the definition of anemia. For example, the prevalence of anemia in CHF patients varies from 4% to 61%. 11 For cancer patients, multicenter studies that have investigated the prevalence of anemia by tumor showed a large variation, not only among tumors, but also within single tumor types. 12 The prevalence of anemia has also been studied in noninstitutionalized persons aged 565 years, reaching 20% at age 585 years. 13 However, no large-scale population data are available for less restricted populations, such as patients managed in internal medicine departments and presenting with various disorders, regarding the prevalence of anemia and patient characteristics. This study population may offer a broad overview on the prevalence of anemia in daily clinical practice.
Therefore, to assess the prevalence, therapeutic management and prognostic significance of anemia in a cohort of patients followed up in internal medicine departments, we conducted a French nationwide cross-sectional and prospective study.
Patients and methods

Study design
The study was divided into two phases, including a cross-sectional study that took place in France in June 2008 (Phase 1), and a prospective longitudinal study over 6 months from June 2008 to December 2008 (Phase 2) During Phase 1, the main objective was to assess the prevalence of anemia in patients managed in internal medicine departments and define the main characteristics of anemic patients. According to the World Health Organization criteria, anemia was defined in Phase 1 as a hemoglobin level <130 g/l in men and <120 g/l in women.
14 During this phase, 106 practitioners from French internal medicine departments (45 from university hospitals and 61 from general hospitals) included 1351 patients, ambulatory or hospitalized, during one full-time day.
For patients included in Phase 2, the main objective was to analyze the prognosis of anemic patients, the course and the prognostic impact of the hemoglobin level on treatment. Only anemic patients with hemoglobin levels <110 g/l were included in Phase 2, as this threshold is often used to guide the prescription of erythropoiesis-stimulating agents, in particular in patients with end-stage renal disease 15 and CHF. 16 During this Phase 2, 89 out of the 106 practitioners (42 from university hospitals and 47 from general hospitals) prospectively followed 389 anemic patients already included in Phase 1 for 6 months.
The patients were ambulatory or hospitalized in internal medicine departments. The study was conducted according to the principles of the Declaration of Helsinki and approved by the local ethics committee.
Clinical and biological data
For each patient included in Phase 1, epidemiological features, personal medical history and biological findings were recorded at the time of the initial evaluation. For those included in Phase 2, data were recorded at baseline, at Months 3 and 6 of follow-up by the practitioners in charge of the patients using a standardized case report form (see Supplementary Data). Clinical data included age, gender and personal medical history. Laboratory evaluation included a full blood count, reticulocytes, serum creatinine level, serum C-reactive protein (CRP) and fibrinogen levels and serum albumin level. Renal failure was defined as a glomerular filtration rate (GFR) <60 ml/min as estimated using the Modification of Diet in Renal Disease (MDRD) simplified formula.
Statistical methods
Descriptive statistics included the mean (SD) or median (range) as appropriate for continuous variables and frequency (%) for categorical variables.
Univariable associations between outcomes (anemia, death and absence of reaching the hemoglobin target goal) and variables were assessed using the two-tailed Fisher's exact test (or chi-squared test when Fisher's exact test was computationally impossible) for categorical variables and Wilcoxon rank test for quantitative variables.
Multiple logistic regressions were used to determine a set of variables independently associated with each outcome. Variables associated with intervention at a 0.05 level and/or known to be clinically pertinent were considered in the multiple models. For those variables, percentages of missing values were <5% except for CRP which presents 11% of missing values. We therefore imputed missing covariates using the 'MICE' method (multiple imputation by chained equations) described by Van Buuren et al. 17 Ten copies of the original data set imputed for missing data were created using 10 iteration of the chained imputation process. A regression analysis combining the results from each data set was undertaken using the Rubin's Rules as recommended. 18 Results based on a complete-case analysis were generally similar. Variable selections were performed using a backward procedure based on a P-value cutoff at 0.05. The validity of final logistic regression models were checked on the complete case data set using le Cessie and van Houwelingen goodness-of-fit test. 19 Odds ratios (ORs) with their 95% confidence intervals (95% CIs) are presented as a measure of association. All tests were two-sided at the 0.05 significance level. Analyses were performed using R 2.11.0 and mice 2.5 statistical packages (online at http://www.R-project.org).
Results
Phase 1: prevalence of anemia and characteristics of patients at baseline
Overall, 1351 patients were included in Phase 1 of the study (Figure 1 ). The main characteristics of the 1351 patients are summarized in Figure 2 .
Demographic features, co-morbidities and laboratory findings associated with the presence of anemia are indicated in Table 1 . Factors significantly associated with anemia according to WHO criteria were older age (67 vs. 57 years, P < 0.001), male gender (52 vs. 43%, P = 0.001), the presence of hematological disorders (23 vs. 15%, P < 0.001), cancer (25 vs. 7%, P < 0.001) and renal failure (42 vs. 28%, P < 0.001). Patients with anemia had lower median GFR (66 vs. 78 ml/min, P < 0.001) and higher serum CRP (16 vs. 5 mg/l, P < 0.001), fibrinogen (4 vs. 3.8 g/l, P = 0.001) and creatinine levels (84 vs. 80 mmol/l, P = 0.008) compared with patients without anemia. Results were quite similar regarding the factors associated with hemoglobin levels (21) 99 (21) 178 (20) 0.89 174 (22) 103 (18) 0.056 Cardiovascular disorder 275 (20) 84 (18) 191 (22) 0.066
166 (21) 109 (19) 0.31 Hematological disorder 273 (20) 70 (15) 203 (23) <0.001
115 (15) 158 (28) <0.001 Malignant 149 (11) 30 (6) 119 (14) <0.001
62 (8) 87 (15) <0.001
Cancer 250 (19) 32 (7) 218 (25) <0.001
86 (11) 164 (29) <0.001 Diabetes 197 (15) 74 (16) 123 (14) 0.47 120 (15) 77 (13) 0.31 Inflammatory disorder 140 (10) 49 (10) 91 (10) 1.00
83 (11) 57 (10) 0.72
Gastrointestinal disorder 119 (9) 34 (7) 85 ( GFR: glomerular filtration rate. P-value in bold when < 0.05.
<110 g/l (Table 1) . Patient characteristics independently associated with anemia (multivariate analysis) according to WHO criteria and with a hemoglobin level <110 g/l are indicated in Table 2 . Using the GFR value, the prevalence OR for anemia was 0.95 (95% CI 0.92-0.97; P < 0.001) according to the WHO criteria and 0.93 (95% CI 0.65-0.72; P < 0.001) for hemoglobin levels <110 g/l, with each 10 ml/min increase in GFR.
Phase 1: management of patients with anemia
Out of the 874 patients with anemia, additional information regarding suspected causes, planned explorations and therapeutic management were available in 696 (80%) anemic patients ( Phase 2: prospective follow-up of patients with anemia
Out of the 573 patients with a hemoglobin level <110 g/l, 389 (68%) patients were included in a prospective longitudinal study for 6 months ( Figure 1 ). The main characteristics of the 389 patients prospectively followed up did not differ a According to the World Health Organization criteria, anemia is defined as a hemoglobin level of <130 g/l in men and <120 g/l in women. b Renal failure was defined as a glomerular filtration rate (GFR) <60 ml/min as estimated using the Modification of Diet in Renal Disease (MDRD) simplified formula. c The prevalence OR for anemia is indicated for each 5 mg/l increase in C-reactive protein. from those of the 184 patients not included in the Phase 2 portion (data not shown). Patients were followed up at Month 3, with an analysis performed of baseline factors associated with the 3-month survival (Table 4) . Patients alive at Month 3 were next followed up at Month 6, with a search performed of predictive factors at Month 3 of the survival at Month 6. At the end of this prospective phase (Month 6), 205 (53%) patients were alive, 70 (18%) had died and 114 (29%) were lost to follow-up. Causes of death were cancer or hemopathy in 30 patients (43%), cardiovascular disorder in 9 (13%), infection in 8 (11%), progressive disorder in 6 (9%), bleeding in 5 (7%), cirrhosis in 1 (1%) and unknown in 11 patients (16%). Causes of anemia identified by physicians in charge of the patients included hematological disorders (19%), renal failure (17%), bleeding (16%), iatrogenic (13%), inflammation (11%), iron/vitamin deficiency (10%), autoimmune disorders (7%) and cancer (4%). The characteristics of the 114 patients lost to follow-up did not significantly differ from those of the remaining 275 patients (data not shown). Baseline factors associated with the 3-month survival were first analyzed by comparing the baseline characteristics of the 260 alive (67%) and the 45 dead patients (12%) (84 patients lost to follow-up at Month 3 were not included in the analysis). Baseline factors associated with survival are indicated in Table 3 . In multivariate analysis, the presence of cancer (OR 0.24, 95% CI 0.12-0.48; P < 0.001), older age (OR 0.97, 95% CI 0.95-0.99; P = 0.003) and a lower target hemoglobin level defined at baseline (OR 1.64, 95% CI 1.14-2.36; P = 0.009) were independently negatively associated with the 3-month survival. Baseline hemoglobin level, GFR and causes of anemia were not associated with the 3-month survival. The same baseline factors were associated with the 6-month survival (data not shown).
The predictive factors at Month 3 of follow-up of the 6-month survival were next analyzed by comparing the characteristics of the 260 patients alive at Month 3 with those of the 205 alive patients and the 25 dead patients at Month 6 (30 patients lost to follow-up at Month 6 were not included in the analysis). In univariate analysis, only age (64.5 years in living patients vs. 75 years in dead patients; P = 0.016) and hemoglobin level at Month 3 (106 vs. 98 g/l; P = 0.003) were associated with the 6-month survival. In multivariate analysis, older age (OR 0.97, 95% CI 0.94-0.99; P = 0.046) and a lower hemoglobin level at Month 3 (OR 1.65, 95% CI 1.2-2.27; P = 0.002) were independently negatively associated with the 6-month survival, after adjustment for cancer (P = 0.43) and target hemoglobin level defined at baseline (P = 0.61). In addition, 35, 31 and 34% of patients alive at Month 6 had completely, partially and not reached the objective of target hemoglobin level at Month 3 as defined by their physician in charge at baseline, respectively, whereas 5, 28 and 67% of dead patients had completely, partially and not reached their objective at Month 3. No specific treatment of anemia, n (%) 186 (27) Iron/vitamin supplements, n (%) 283 (41) Iron, n (%) 217 (31) Folic acid, n (%) 116 (17) Vitamin B12, n (%) 36 (5) Blood transfusion, n (%) 204 (29) Erythropoietin, n (%) 163 (23) Corticosteroids, n (%) 64 (9) a Level of hemoglobin targeted by the physician in charge of the anemic patients. According to the World Health Organization criteria, anemia is defined as a hemoglobin level of <130 g/l in men and <120 g/l in women.
Discussion
In the present study, we analyzed the prevalence, therapeutic management and prognostic significance of anemia in a cohort of ambulatory and hospitalized patients followed up in internal medicine departments. The most striking conclusions drawn are (i) the high prevalence of anemia in patients managed in internal medicine departments and presenting with various disorders, (ii) the detailed profile of anemic patients, (iii) the baseline prognostic factors associated with survival at Month 3 and (iv) the favorable prognostic impact of reaching the target hemoglobin level defined by the physician in charge at Month 3 for 6-month survival. Although the prevalence of anemia has been studied in CKD and CHF patients, with extreme variation between studies, no large-scale population data were available for less restricted populations with various disorders. The inclusion of patients with various disorders could be a limitation, but we chose in the present study to include ambulatory and hospitalized patients managed in internal medicine departments because, this population may offer a broader view on the prevalence of anemia in daily clinical practice. We found that 65% of our patients were anemic according to the WHO criteria, whereas 43% had hemoglobin levels <110 g/l, which supports the need to improve the management of anemia in these patients. Our findings are consistent with studies focusing on well-defined populations, such as CKD patients, in whom anemia was present in almost 50%, 10 or CHF patients, in whom anemia was present in 4-61%. 11 In these well-defined populations, correction of anemia was associated with an improvement of symptoms, functional capacity and quality of life, 20, 21 suggesting the need for well-designed studies in order to assess the benefits of such strategies in less restricted populations. Besides the high prevalence of anemia in our study population, the presence of anemia was significantly associated with cancer, hematological disorders, chronic gastrointestinal disorders, renal failure, cardiovascular disorders, male gender and inflammatory syndrome. Only cancer, hematological disorders, renal failure and inflammatory syndrome were significantly associated with hemoglobin levels <110 g/l. These findings are consistent with previous studies evaluating factors associated with anemia, and reflect either causal factors for anemia and/or co-morbidities frequently associated with anemia. [22] [23] [24] These results suggest that the diagnosis and management of anemia should concern primarily these patients, and further studies should probably focus on patients displaying one or more of these factors.
We next assessed the prognostic significance of anemia and its course during the follow-up for the 3-month and 6-month survival in a prospective phase of the study. At baseline, we found that the presence of cancer, older age and a lower target hemoglobin level were independently associated with death at Month 3, whereas baseline hemoglobin level, renal function and causes of anemia were not associated with the 3-month survival. Although the presence of cancer and older age have been largely reported as prognostic factors, the prognostic significance of the target hemoglobin level defined at baseline in non-CKD and non-CHF populations is of particular interest. In patients with CKD, many studies have evaluated the optimal target hemoglobin level. An early complete correction of anemia (target hemoglobin value between 130 and 150 g/l) did not reduce the risk of cardiovascular events compared with a subnormal target hemoglobin value between 105 and 115 g/l, although it significantly improved the general health and physical function. 25 A recent meta-analysis suggests that targeting hemoglobin levels in excess of 120 g/l leads to small and not clinically meaningful improvements in health-related quality of life. 26 In addition, in cancer patients, the initiation of erythropoiesis-stimulating agents was shown to be beneficial and should be initiated when the hemoglobin level drops below 100 g/l, with a target hemoglobin level that should not exceed 120 g/l. 27 These findings and our data suggest that a target hemoglobin level between 110 and 120 g/l could be beneficial in patients presenting with various disorders, as in our study population.
We also analyzed the factors at Month 3 of follow-up that were predictive of the 6-month survival. We found that older age and a lower hemoglobin level at Month 3, below the target hemoglobin level defined at baseline, were independently associated with death at Month 6, after adjustment for predictive factors of survival identified at baseline. Besides the interest at baseline of having a sufficient target hemoglobin value, these results suggest that the correction of anemia within target values at Month 3 is critical for short-term survival, independent of co-morbidities, the cause and/or severity of anemia.
We must acknowledge some limitations of this study, including the inclusion of patients with various disorders, the absence of long-term follow-up and the high number of patients lost to follow-up in the second phase. However, the present study also has some strengths: the unrestricted study population, as it represents real-life patients managed in daily practice; the high number of patients included in this survey; and the clear recommendations suggested by our findings, which should help physicians from hospital department of internal medicine in their daily practice with anemic patients. Last, this study describes the real-life management of patients followed up in French internal medicine departments and constitutes interesting data for conducting well-designed studies in order to improve the management of anemic patients.
In conclusion, anemia is very frequent in patients from internal medicine departments presenting with various disorders. The presence of anemia is associated with cancer, hematological disorders, renal failure and inflammatory syndrome. At baseline, the main prognostic factors for the 3-month survival include the presence of cancer, older age and a lower target hemoglobin level, while reaching the target hemoglobin level at Month 3 may have a favorable prognostic impact on the 6-month survival. Randomized controlled trials in such population are needed to confirm these findings.
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